Track Order   | Customer Support   | Request Book   |
International Order
Non-Myeloablative Allogeneic Transplantation 1st Editon 2012 Softbound at Meripustak

Non-Myeloablative Allogeneic Transplantation 1st Editon 2012 Softbound

Books from same Author: Asad Bashey, Edward D. Ball

Books from same Publisher: Springer

Related Category: Author List / Publisher List

  • Retail Price: ₹ 13529/- [ 5.00% off ]

    Seller Price: ₹ 12853

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 5.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 5.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available


Click for International Orders
  • Provide Fastest Delivery
  • 100% Original Guaranteed
    • General Information  
    Author(s)Asad Bashey, Edward D. Ball
    PublisherSpringer
    Edition1st Edition
    ISBN9781461353041
    Pages216
    BindingSoftbound
    LanguageEnglish
    Publish YearOctober 2012

    Description

    Springer Non-Myeloablative Allogeneic Transplantation 1st Editon 2012 Softbound by Asad Bashey, Edward D. Ball

    Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use. 1 Development of allogeneic hematopoietic stem cell transplantation (HSCT).- 2 Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in nonmyeloablative hematopoietic cell transplantation.- 3 Mobilization of allogeneic peripheral blood progenitor cells.- 4 Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologicmalignancies in experimental and clinical studies.- 5 Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.- 6 Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.- 7 Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy.- 8 Outpatient allografting in hematologic malignancies and nonmalignant disorders — applying lessons learned in the canine model to humans.- 9 Non-myeloablative transplants for congenital diseases.